Overview
The primary objective is to investigate the association between temporal evolutions of blood biomarkers and clinical adverse events, in order to produce a dynamic, individual, and accurate prediction model for patients with HFpEF.
Moreover several secondary objectives will be investigated.
Description
This is a prospective, observational multi-center cohort study which will be conducted at the cardiology departments of the Erasmus Medical Centre (EMC) as well as five other hospitals. A total of 200 HFpEF patients will be included in the study via the outpatient clinics. The follow-up period will constitute a minimum of 2 years and a maximum of 3.5 years. Clinical data will be collected at baseline and blood samples will be collected at baseline and subsequently every 6 months.
Eligibility
Inclusion Criteria:
- Age of 18 years or older
- Capable of understanding and signing informed consent
- A diagnosis of HFpEF according to the HFA-PEFF diagnostic algorithm of the ESC or/and a high (90%) probability of HFpEF according to the H2FPEF score, i.e. a score of 6 or higher.
Exclusion Criteria:
- History of LVEF ≤40%
- Scheduled for surgery or intervention for both coronary and non-coronary indication within 6 months of inclusion
- Impaired renal function, defined as eGFR < 20 mL/min/1.73 m2 (CKD-EPI) or requiring dialysis at the time of screening
- Acute or chronic liver disease, defined by serum levels of transaminases or alkaline phosphatase more than three times the upper limit of normal at screening
- COPD Gold stage IV
- Congenital heart disease
- Pregnancy
- Coexistent condition with life expectancy of <1 year
- Unlikely to appear at all scheduled follow-up visits
- Linguistic barrier